ReviewEuropean journal of pediatrics2025
Contribution of omics to the pathophysiology of diaphragmatic hernias: a narrative review.
Review in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital diaphragmatic hernia (CDH), a rare defect (1/2000-1/4000 births), results from a diaphragmatic malformation allowing abdominal organs to invade the thorax. Despite progress in fetal and neonatal care, mortality reaches 30-40%, with survivors often facing chronic complications. Although chromosomal and monogenic anomalies suggest a genetic origin, CDH's pathophysiology remains poorly understood and multifactorial. Omics technologies (genomics, transcriptomics, and proteomics) provide potentially powerful tools to decode its molecular mechanisms and discover predictive biomarkers for precision medicine. This review integrates well known genetic knowledge as well as recent omics advancements. Transcriptomics and proteomics uncover dysregulated pathways, microRNAs, and proteins linked to diaphragmatic development, its complications, such as pulmonary hypoplasia, and potential therapeutic targets.
conclusionMulti-omics integration highlights CDH's complexity. Despite challenges like animal model limitations and biomarker accessibility, omics offers promising avenues-for prenatal counselling, risk stratification, and potential targeted therapies-ultimately improving clinical outcomes. WHAT IS KNOWN: • CDH exhibits marked genetic heterogeneity, as it is associated with both chromosomal abnormalities and monogenic syndromes, yet no single gene explains more than 1-5% of cases. • High-throughput omics technologies in precision medicine have already identified therapeutic targets and helped better comprehension of pathophysiological mechanism. WHAT IS NEW: • Multi-Omics integration in CDH research by combining genomics, transcriptomics, and proteomics uncovers dynamic mechanisms and therapeutic targets - such as miR-200b and STAT3 tested in animal models. • Proteomic and transcriptomic biomarkers in fetal biological fluids may enable to monitor prenatal therapeutic efficiency and perinatal outcomes.
Indexed as
Identifiers
41299117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.